Filing Analysis
Turn Therapeutics Inc. filed an 8-K to furnish an updated investor presentation released on June 1, 2026. The filing serves as a formal disclosure of information shared with investors to ensure compliance with Regulation FD.
📋 Key Facts
- The company released an updated investor presentation on June 1, 2026.
- The presentation is attached as Exhibit 99.1.
- The filing was signed by CEO Bradley Burnam on June 3, 2026.
Turn Therapeutics Inc. filed an 8-K to furnish a press release issued on June 1, 2026. The filing serves as a formal disclosure of information under Regulation FD.
📋 Key Facts
- The filing date is June 1, 2026.
- The company furnished a press release as Exhibit 99.1.
- The information is provided under Item 7.01 (Regulation FD Disclosure), meaning it is 'furnished' rather than 'filed' for Section 18 liability purposes.
Turn Therapeutics Inc. filed an 8-K to furnish a press release issued on May 27, 2026. The filing is specifically categorized under Item 7.01, meaning the information is furnished rather than filed, and the company explicitly states that the information is not subject to the liabilities of Section 18 of the Exchange Act.
📋 Key Facts
- The filing date is May 27, 2026.
- The company is an 'Emerging Growth Company'.
- The primary purpose of is to furnish a press release (Exhibit 99.1).
- The information is furnished under Item 7.01 (Regulation FD Disclosure).
Turn Therapeutics Inc. filed a Form 8-K on May 19, 2026, to disclose a press release under Regulation FD. The specific contents of the press release were not detailed in the main body of the filing.
📋 Key Facts
- Turn Therapeutics Inc. issued a press release on May 19, 2026.
- The press release was furnished as Exhibit 99.1 under Item 7.01.
- The filing was signed by Bradley Burnam, Chief Executive Officer.
Turn Therapeutics Inc. issued a press release on May 18, 2026, which was furnished to the SEC under Regulation FD disclosure requirements.
📋 Key Facts
- The company issued a press release on May 18, 2026.
- The filing was made under Item 7.01 (Regulation FD Disclosure).
- Exhibit 99.1 contains the full text of the press release.
- The information is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Turn Therapeutics Inc. announced its financial and operating results for the first quarter ended March 31, 2026. The disclosure was made via a press release furnished as an exhibit to the filing.
📋 Key Facts
- Financial results reported for the quarter ended March 31, 2026.
- The report was filed on May 11, 2026, under Item 2.02.
- Turn Therapeutics is classified as an emerging growth company.
- The company is listed on The Nasdaq Stock Market LLC under the ticker TTRX.
Turn Therapeutics Inc. announced its financial and operating results for the fiscal year ended December 31, 2025, via a press release furnished with the filing.
📋 Key Facts
- The filing reports financial results for the fiscal year ended December 31, 2025.
- The press release was issued and the 8-K filed on March 31, 2026.
- The company is classified as an emerging growth company.
Turn Therapeutics entered into a $25 million loan and security agreement with Avenue Venture Opportunities Fund II, L.P., securing an initial $7 million tranche. The debt is high-cost, secured by all company assets including intellectual property, and includes significant dilutive components such as an upfront equity grant and a discounted conversion option.
🚩 Red Flags
- High interest rate (minimum 12.25%) relative to traditional corporate debt.
- Significant dilution risk from the $1.2M upfront equity grant and the 20% discount on the debt conversion option.
- All intellectual property is pledged as collateral, creating high risk in the event of default.
- Future funding tranches are conditional on milestones, which may create liquidity pressure if clinical trials face delays.
📋 Key Facts
- Total loan facility of up to $25.0 million across three tranches, with $7.0 million funded immediately.
- Interest rate is the greater of (Prime + 5.50%) or 12.25% per annum.
- The loan is secured by a lien on all company assets, including intellectual property.
- Issued $1.2 million in common stock to the lender as an upfront equity grant.
- Lender has a conversion option for up to $3.0 million of principal at a 20% discount to the market price (80% of closing price).
- Tranches 2 ($8M) and 3 ($10M) are contingent upon clinical and financing milestones.
- Maturity date is set for October 1, 2029, with a final payment fee of 3.75% of the total funded amount.